您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 欧洲共同体药房
产地国家: 欧洲共同体国家
所属类别: 糖尿病->2型糖尿病
处方药:处方药
包装规格: 3毫克/片 28片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
赛诺菲安万特
生产厂家英文名:
Sanofi-Aventis Deutschland GmbH
该药品相关信息网址1:
http://www.drugs.com/amaryl.html
该药品相关信息网址2:
http://www.rxlist.com/amaryl-drug.htm
原产地英文商品名:
AMARYL 3mg/Tab 28Tabs/box
原产地英文药品名:
GLIMEPIRIDE
中文参考商品译名:
亚莫利 3毫克/片 28片/盒
中文参考药品译名:
格列美脲
中文参考化合物名称:
1-[4-[2-(3-乙基-4-甲基-2-氧代-3-吡咯啉-1-甲酰胺基)-乙基]-苯磺酰]-3-(反式-4-甲基环己基)-脲
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Type 2 diabetes
临床试验期:
完成
中文适应病症参考翻译1:
2型糖尿病
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20096721474825.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文格列美脲处方资料(仅供参考)

【药品名称】
  通用名:格列美脲片(亚莫利)
  英文名:Glimepiride Tablets
  汉语拼音:Geliemeiniao Pian
  本品主要成份为:格列美脲。其化学名称为:1-[4-[2-(3-乙基-4-甲基-2-氧代-3-吡咯啉-1-甲酰胺基)-乙基]-苯磺酰]-3-(反式-4-甲基环己基)-脲。

【性状】
  本品为白色片。

【作用机理】
  本品为第三代磺酰脲类口服降血糖药,其降血糖作用的主要机理是刺激胰岛B细胞分泌胰岛素,同时提高周围组织对胰岛素的敏感性。这就是亚莫利的双重作用机制。本品与胰岛素受体结合及解离的速度较格列本脲为快,较少引起较重低血糖。

【药代动力学】
  本品口服后迅速而完全吸收,空腹或进食时服用对本品的吸收无明显影响,服后2~3小时达血药峰值,口服4mg平均峰值约为300ng/ml,t1/2约5~8小时。但因为生理性的缓释作用,所以每天只需服用一次。本品在肝脏内经P450氧化物代谢成无降糖活性的代谢物,60%经尿排泄,40%经粪便排泄。

【适应症】
  适用于食物、运动疗法及减轻体重均不能满意控制血糖的2型糖尿病。

【禁 忌】1.对本品任何成份过敏者。2.1型糖尿病、糖尿病昏迷、酮症酸中毒、严重的肾脏或肝功能损害,对格列美脲、其它磺脲类、磺胺类或赋形剂过敏者。3.对于严重肾脏或肝功能损害的病人,应改用胰岛素治疗。4.格列美脲片禁用于妊娠和哺乳病人。

【用法用量】
  遵医嘱口服用药。对于糖尿病患者,格列美脲或任何其他降糖药物都无固定剂量,必须定期测量空腹血糖和糖化血红蛋白以确定患者用药的最小有效剂量;测定糖化血红蛋白水平以监测患者的治疗效果。
  通常起始剂量:在初期治疗阶段,格列美脲的起始剂量为1~2mg,每天一次,早餐时或第一次主餐时给药。那些对降糖药敏感的患者应以1mg每天一次开始,且应谨慎调整剂量。格列美脲与其他口服降糖药之间不存在精确的剂量关系。格列美脲最大初始剂量不超过2mg。
  通常维持剂量:通常维持剂量是1~4mg每天一次,推荐的最大维持量是8mg每天一次。剂量达到2mg后,剂量的增加根据患者的血糖变化,每1~2周剂量上调不超过2mg。

GENERIC NAME: glimepiride

BRAND NAME: Amaryl

DRUG CLASS AND MECHANISM: Glimepiride is an oral blood sugar-lowering drug in a class of medicines for controlling diabetes called sulfonylureas. Glimepiride is related to other sulfonylureas including glyburide (Micronase; Diabeta), glipizide (Glucotrol), tolbutamide (Orinase) and tolazamide (Tolinase).

Glimepiride is used in type II diabetes, the most common type of diabetes that is found in 90% of patients with diabetes. In type II diabetes, insulin usually is not necessary to control the blood sugar. Instead, diet and oral medications often are sufficient. Intolerance to sugar that results in elevated blood sugar is caused by reduced insulin secretion by the pancreas and resistance to insulin's effects by the body's cells. Glimepiride lowers the sugar level in the blood by stimulating insulin to be secreted from the pancreas into the blood. Insulin causes sugar to leave the blood and enter cells throughout the body. Glimepiride was approved by the FDA in December of 1995.

GENERIC AVAILABLE: Yes

PRESCRIPTION: Yes

PREPARATIONS: Tablets: 1mg, 2mg, 4mg.

STORAGE: Tablets should be stored below 86 F (30 C).

PRESCRIBED FOR: It is believed that control of blood sugar in people with diabetes decreases the risks of eye, kidney, and nerve damage. Glimepiride is used to treat type II diabetes that cannot be controlled by a strict diabetes diet alone. If sulfonylureas are not effective, other oral drugs or insulin may be used.

DOSING: Like other medicines used to treat diabetes, the dose of glimepiride is individualized using periodic measurements of blood sugar to determine the best dose.

DRUG INTERACTIONS: Medicines that can increase blood sugar can reverse the action of glimepiride. These drugs include diuretics [for example, hydrochlorothiazide (Hydrodiuril, Ezide, Hydro-Par, Microzide, and many combinations with other drugs), furosemide (Lasix)], corticosteroids such as prednisone and methylprednisolone (Medrol)], phenytoin (Dilantin), niacin, and sympathomimetics such as pseudoephedrine (Sudafed).

Beta-blockers such as propranolol (Inderal) and atenolol (Tenormin) can cause low or high blood sugar. Additionally, they can directly reverse the sugar-lowering effect of sulfonylureas and render them less effective. Beta-blockers also can blunt some of the body's protective responses to low blood sugar, thus making it difficult for patients to recognize reactions due to low blood sugar. This notwithstanding, beta-blockers have been used successfully in patients with diabetes and have been associated with improved survival in patients with diabetes with high blood pressure.

Rifampin increases the breakdown of two other sulfonylureas, tolbutamide (Orinase) and glyburide (Diabeta, Micronase). This might interfere with the effects of the drugs and result in higher levels of sugar in the blood. Although this same interference has not yet been reported with glimepiride, the possibility that it may occur should be kept in mind.

PREGNANCY: In animal studies, glimepiride and other sulfonylureas have been associated with a higher risk of fetal death. However, there have been no good studies in women. On the other hand, abnormal blood sugar concentrations (high or low) during pregnancy increase the risk of abnormalities in the fetus. Therefore, physicians must carefully weigh the benefits and risks of sulfonylurea treatment during pregnancy.

NURSING MOTHERS: It is not known if glimepiride is excreted in breast milk like other sulfonylureas. Because of the risk of low blood sugar in the infant, it is recommended that glimepiride be discontinued in nursing mothers. If therapy other than diet and exercise is needed, insulin is recommended.

SIDE EFFECTS: Low blood sugar (hypoglycemia) can occur during glimepiride therapy. Symptoms of low blood sugar include hunger, nausea, tiredness, perspiration, headache, heart palpitations, numbness around the mouth, tingling in the fingers, tremors, muscle weakness, blurred vision, cold temperature, excessive yawning, irritability, confusion, or loss of consciousness. Other side effects include dizziness (1 of every 60 persons), headache (1 of every 75), and nausea or vomiting (1 of every 90). A rash occurs in fewer than 1 of every 100 persons who receive glimepiride. Glimepiride is a derivative of a sulfonamide drug. People allergic to other sulfonamide-related drugs may develop an allergic reaction to glimepiride.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20096721474825.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2012-6-19
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com